Heart valve study halted early: which blood thinner is safer?
NCT ID NCT02817789
First seen May 14, 2026 · Last updated Jun 23, 2026 · Updated 8 times
Summary
This study compared two antiplatelet drug regimens after transcatheter aortic valve implantation (TAVI) for aortic stenosis. One group received ticagrelor alone, the other received aspirin plus clopidogrel. The goal was to see which caused fewer serious complications like bleeding, stroke, or kidney injury. However, the trial was terminated early after enrolling only 50 of the planned 308 participants, so no firm conclusions can be drawn.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AORTIC VALVE STENOSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
APHM
Marseille, 13005, France
-
APHP
Paris, 75013, France
-
CHRU de Lille
Lille, 59037, France
-
CHRU de Nîmes
Nîmes, 30029, France
-
CHU de Bordeaux
Pessac, 33604, France
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ticagrelor (antiplatelet drug) compared to a combination of lysine acetylsalicylate (aspirin) and clopidogrel (antiplatelet drug)
What this could lead to
If successful, this could identify a safer antiplatelet regimen after TAVI, reducing bleeding and stroke risks.
What could go wrong
The trial was terminated early with only 50 participants, so results are very limited. It is unclear if ticagrelor alone is truly safer or effective.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.